SEC Form 4 · accession 0001104659-17-032415
Aralez Pharmaceuticals Inc. · ARLZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark A Glickman
Officer — Chief Commercial Officer
Period of report
May 11, 2017
Accepted (ET)
May 12, 2017 · 9:52 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001660719
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares, without par valueF2 | May 11, 2017 | A | 80,163 | $0.00 | A | 255,913 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F3 | $1.56 | May 11, 2017 | A | 92,621 | A | — | May 11, 2027 | Common Shares, without par value | 92,621 | 92,621 | D |
Explanation of responses
- F1Restricted Stock Units granted pursuant to the Aralez Pharmaceuticals Inc. 2016 Amended and Restated Long-Term Incentive Plan, which vest in substantially equal annual installments over the three years immediately following the date of grant, subject to continued employment or service to the Company.
- F2Includes 58,380 shares of Common Stock and 197,533 Restricted Stock Units.
- F3The option vests as to 25% of the shares on May 11, 2018, and the remainder vests in substantially equal installments over the 36 months immediately following such date, subject to continued employment or service to the Company.